A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma - Top-Institutions - MDSpire

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma

  • By

  • Kartik Sehgal

  • Anthony Serritella

  • Mofei Liu

  • Anne ONeill

  • Chaitali Nangia

  • Theodora Pappa

  • Michael J Demeure

  • Francis P Worden

  • Robert I Haddad

  • Jochen Lorch

  • June 29, 2024

  • 0 min

Share

Top Institutions in Endocrinology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Endocrine Oncology
    • Thyroid Cancer
    • Clinical Trials

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Endocrine Oncology
    • Thyroid Cancer
    • Translational Research

  • #3

    Dana-Farber Cancer Institute / Brigham and Women’s Hospital
    Dana-Farber Cancer Institute / Brigham and Women’s Hospital

    Boston, MA

    Key Differentiators

    • Endocrine Oncology
    • Thyroid Cancer
    • Clinical and Translational Research

  • #4

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Endocrine Surgery
    • Thyroid Cancer
    • Molecular Oncology

Original Source(s)

A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma

  • by Kartik Sehgal, Anthony Serritella, Mofei Liu, Anne ONeill, Chaitali Nangia, Theodora Pappa, Michael J Demeure, Francis P Worden, Robert I Haddad, Jochen Lorch

  • June 29, 2024

Related Content

A Multicenter, Clinically Interpretable Prediction Model for Malignancy Risk in C-TIRADS 3–4 Thyroid Nodules

Approach to the Pediatric Patient With Thyroid Nodules

When Thyroid and Parathyroid Collide

Pathologists report the first case of papillary thyroid carcinoma invading an intrathyroidal parathyroid adenoma